Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
© 2023. The Author(s)..
Following primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 16. Mai, Seite 2799 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 19.09.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-38275-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35696325X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35696325X | ||
| 003 | DE-627 | ||
| 005 | 20231226071552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-38275-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM35696325X | ||
| 035 | |a (NLM)37193713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Following primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Matthews, Philippa C |e verfasserin |4 aut | |
| 700 | 1 | |a Stoesser, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Newton, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Studley, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, John I |e verfasserin |4 aut | |
| 700 | 1 | |a Farrar, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Kolenchery, Jaison |e verfasserin |4 aut | |
| 700 | 1 | |a Marsden, Brian D |e verfasserin |4 aut | |
| 700 | 1 | |a Hoosdally, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, E Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, Derrick W |e verfasserin |4 aut | |
| 700 | 1 | |a Peto, Tim E A |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, A Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Pouwels, Koen B |e verfasserin |4 aut | |
| 700 | 1 | |a Eyre, David W |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Infection Survey team |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Tina |e investigator |4 oth | |
| 700 | 1 | |a Ayoubkhani, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Black, Russell |e investigator |4 oth | |
| 700 | 1 | |a Felton, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Crees, Megan |e investigator |4 oth | |
| 700 | 1 | |a Jones, Joel |e investigator |4 oth | |
| 700 | 1 | |a Lloyd, Lina |e investigator |4 oth | |
| 700 | 1 | |a Sutherland, Esther |e investigator |4 oth | |
| 700 | 1 | |a Pritchard, Emma |e investigator |4 oth | |
| 700 | 1 | |a Vihta, Karina-Doris |e investigator |4 oth | |
| 700 | 1 | |a Doherty, George |e investigator |4 oth | |
| 700 | 1 | |a Kavanagh, James |e investigator |4 oth | |
| 700 | 1 | |a Chau, Kevin K |e investigator |4 oth | |
| 700 | 1 | |a Hatch, Stephanie B |e investigator |4 oth | |
| 700 | 1 | |a Ebner, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Lucas Martins |e investigator |4 oth | |
| 700 | 1 | |a Christott, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Dejnirattisai, Wanwisa |e investigator |4 oth | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e investigator |4 oth | |
| 700 | 1 | |a Cameron, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Tamblin-Hopper, Phoebe |e investigator |4 oth | |
| 700 | 1 | |a Wolna, Magda |e investigator |4 oth | |
| 700 | 1 | |a Brown, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Cornall, Richard |e investigator |4 oth | |
| 700 | 1 | |a Screaton, Gavin |e investigator |4 oth | |
| 700 | 1 | |a Lythgoe, Katrina |e investigator |4 oth | |
| 700 | 1 | |a Bonsall, David |e investigator |4 oth | |
| 700 | 1 | |a Golubchik, Tanya |e investigator |4 oth | |
| 700 | 1 | |a Fryer, Helen |e investigator |4 oth | |
| 700 | 1 | |a Cox, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Paddon, Kevin |e investigator |4 oth | |
| 700 | 1 | |a James, Tim |e investigator |4 oth | |
| 700 | 1 | |a House, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Robotham, Julie |e investigator |4 oth | |
| 700 | 1 | |a Birrell, Paul |e investigator |4 oth | |
| 700 | 1 | |a Jordan, Helena |e investigator |4 oth | |
| 700 | 1 | |a Sheppard, Tim |e investigator |4 oth | |
| 700 | 1 | |a Athey, Graham |e investigator |4 oth | |
| 700 | 1 | |a Moody, Dan |e investigator |4 oth | |
| 700 | 1 | |a Curry, Leigh |e investigator |4 oth | |
| 700 | 1 | |a Brereton, Pamela |e investigator |4 oth | |
| 700 | 1 | |a Jarvis, Ian |e investigator |4 oth | |
| 700 | 1 | |a Godsmark, Anna |e investigator |4 oth | |
| 700 | 1 | |a Morris, George |e investigator |4 oth | |
| 700 | 1 | |a Mallick, Bobby |e investigator |4 oth | |
| 700 | 1 | |a Eeles, Phil |e investigator |4 oth | |
| 700 | 1 | |a Hay, Jodie |e investigator |4 oth | |
| 700 | 1 | |a VanSteenhouse, Harper |e investigator |4 oth | |
| 700 | 1 | |a Lee, Jessica |e investigator |4 oth | |
| 700 | 1 | |a White, Sean |e investigator |4 oth | |
| 700 | 1 | |a Evans, Tim |e investigator |4 oth | |
| 700 | 1 | |a Bloemberg, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Allison, Katie |e investigator |4 oth | |
| 700 | 1 | |a Pandya, Anouska |e investigator |4 oth | |
| 700 | 1 | |a Davis, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Conway, David I |e investigator |4 oth | |
| 700 | 1 | |a MacLeod, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Cunningham, Chris |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 16. Mai, Seite 2799 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:16 |g month:05 |g pages:2799 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-38275-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 16 |c 05 |h 2799 | ||